

MEDICATION CHART (OPIOIDS, BENZODIAZEPINES, OTHER) (This chart is intended for clinicians who provide primary care to pregnant and postpartum women)

Data current as of December 2016

| | | | | | Breastfeeding | | |
|-------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|----------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------|
| Generic Name | Trade Name | Usual Daily Dose | Maternal Risks | Fetal/Neonatal Risks | Relative infant dose=(RID) | Half-life (t _{1/2})/ metabolites | Reported side effects in breastfed infants |
| Abrupt discontinuati | on may precipitate | I medications listed. withdrawal symptoms. ence syndrome (NAS)/neonata | l opioid withdrawal syndrome | (NOWS). | | | |
| Buprenorphine | Subutex®, Suboxone® (contains naloxone) | 4-24 mg for opioid dependence | Side effects include sedation, dizziness, headache, nausea, and constipation | Somatosensory disruption | 0.09-1.9% | • 24–48 hr • 34 hr metabolite | May moderate NAS symptoms |
| Codeine sulfate | various | 60-360 mg for pain | Side effects include sedation | Respiratory depression | 0.6-8.1% | • 3 hr | Not recommendedCNS depressionApneaSedation |
| Fentanyl | Actiq®, Duragesic®, Sublimaze® | Patches deliver range of doses from 12 mcg/hr to 100 mcg/hr Patches are typically changed q72hr | Side effects include nausea and constipation, sedation | CNS depression | 2.9-5% | • 4 hr • 20-27 h | Sedation Respiratory depression |
| Hydrocodone/ acetaminophen | Vicodin®, Lortab® | 10-60 mg for pain | Side effects include sedation, nausea, and vomiting | Respiratory depression | 2.2-3.7% | • 4 hr | Possible sedation |
| Meperidine | Demerol® | 200-400 mg for pain | Dose may require adjustment during pregnancy | • CNS depression | 1.1-13% | • 2-4 hr • 15-30 hr metabolite | Not recommended CNS depression |
| Methadone | Dolophine®, Methadose® | 20-300 mg for pain, opioid dependence | Side effects include anxiety, confusion, constipation | • Preterm birth | 1.9-6.5% | • 13-55 hr | May moderate NAS symptoms Maternal dose may need to be decreased post-partum |
| Morphine | Duramorph®, Roxanol® | 30-180 mg (PO) for pain | Side effects include sedation, cramps, constipation, weight loss | • Low birth weight | 9-35% | • 1.5-2 hr | Sedation CNS depression |
| Oxycodone | OxyContin®, Per- codan®, Percocet® | 5-60 mg for pain | Side effects include sedation, pruritus, nausea, vomiting, and constipation | • Decreased head size | 1-8% | • 2.0-4.4 hr | Sedation CNS depression |
| Oxymorphone | Opana® | 20-60 mg for pain | Side effects include sedation, pruritus, nausea, vomiting, and constipation | No adverse morphologic consequences reported | N/A | • 7.3-9.4 hr | Sedation Respiratory depression |
| Tramadol | Ultram® | 200-400 mg for pain | Side effects include agitation, anxiety, pruritus, tremor, nausea, vomiting, diarrhea, and constipation | No adverse morphologic consequences reported | 2.9% | • 7 hrs • 85 hrs metabolites | Limited data, consider alternative Monitor for sedation and respiratory depression |



MEDICATION CHART (OPIOIDS, BENZODIAZEPINES, OTHER) (This chart is intended for clinicians who provide primary care to pregnant and postpartum women)

Data current as of December 2016

| | | | | | Breastfeeding | | | |
|----------------------|-------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------|--|
| Generic Name | Trade Name | Usual Daily Dose | Maternal Risks | Fetal/Neonatal Risks | Relative infant dose=(RID) | Half-life (t _{1/2})/ metabolites | Reported side effects in breastfed infants | |
| DRUG CLASS: Benzodia | azepines (If necessa | ry to use during breastfeeding, | , consider short-term or intern | nittent use with shorter-acting drugs.) | | | | |
| Alprazolam | Xanax® | 0.75-4 mg for anxiety, panic disorder | Side effects include sedation, sedation, dizziness, headache, memory impairment | Congenital anomalies Withdrawal | 8.5% | • 11-15 hr | Preferred, if used intermittently Withdrawal Sedation | |
| Chlordiazepoxide | Librium® | 15–100 mg for anxiety | Side effects include sedation, dizziness, headache, confusion, insomnia | Congenital anomalies Withdrawal | N/A | • 7-28 hr • 14-95 hr metabolites | Not preferred agent (long half-life) Unknown Active metabolites | |
| Clonazepam | Klonopin® | 0.5-4.0 mg for panic disorder | Side effects include ataxia, dizziness, and sedation | Congenital heart diseaseRespiratory depressionHypotoniaWithdrawal | 2.8% | • 18-50 hr | Use with caution Apnea, periodic breathing CNS depression | |
| Diazepam | Valium® | 4–40 mg for anxiety | Side effects include sedation and hypotonia | Low birth weight Decreased tone Withdrawal | 0.9-7% | • 30-40 hr | Use with caution Lethargy, sedation, and weight loss Active metabolites | |
| Lorazepam | Ativan® | 2-6 mg for anxiety, insomnia | Side effects include sedation, agitation, and tremor | Anal atresiaRespiratory depressionWithdrawalFeeding difficulties | 2.6-2.9% | • 12 hr • 12-18 hr metabolite | Preferred over longer acting agents No adverse effects reported | |
| Temazepam | Restoril® | 7.5–30 mg for insomnia | Side effects include lethargy, insomnia, irritability, dizziness | Respiratory depression Withdrawal | N/A | • 3–18 hr • 2 hr metabolites | Short acting, limited data available Sedation Feeding difficulties | |
| DRUG CLASS: Other | | | | | | | | |
| Diphenhydramine | Benedryl®, Nytol®, Nyquil® | 25–300 mg for insomnia, cough, cold symptoms | Side effects include sedation and thickening of bronchial secretions Possible decreased breast milk production | Cleft palate CNS depression | 0.7-1.4% | • 48 hr • Up to 10.4 hr metabolite | Sedation Poor feeding Anecdotal concerns of decreasing milk supply Consider non-sedating antihistamines | |
| Doxylamine | Dozile®, Unisom® | 25mg for insomnia or nausea and vomiting of pregnancy | Major effect is sedation Possible decreased breast milk production | No reports of adverse effects Recommended medication for nausea/ vomiting in pregnancy | N/A | • 10-13 hr | Sedation or irritability with higher doses or prolonged use | |



MEDICATION CHART (OPIOIDS, BENZODIAZEPINES, OTHER) (This chart is intended for clinicians who provide primary care to pregnant and postpartum women)

Data current as of December 2016

| | | | | | | Breastfeeding | | |
|-------------------|---------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Generic Name | Trade Name | Usual Daily Dose | Maternal Risks | Fetal/Neonatal Risks | Relative infant dose=(RID) | Half-life (t _{1/2})/ metabolites | Reported side effects in breastfed infants | |
| DRUG CLASS: Other | | | | | | | | |
| Doxepin | Silenor®, Adapin®, Sinequan® | 25–300 mg for anxiety, depression, insomnia | Major effect is sedation | No reports of adverse effects CNS depression | 0.3-3% | • 15 hr • 31 hr metabolite | ContraindicatedRespiratory depressionHypotoniaSedationIrritabilityActive metabolite | |
| Trazodone | Desyrel®, Donaren® | 150-400 mg for insomnia; depression | Side effects include sedation, headache, dizziness, blurred vision, nausea, vomiting | No reports of adverse effects Withdrawal | 2.8% | • 4-9 hr | Possible sedation Irritability | |
| Zaleplon | Sonata® | 10-20 mg for insomnia | Major effect is sedation Side effects include amnesia and dizziness | No reports of adverse effects | 1.5% | • 1 hr | Possible sedation | |
| Zolpidem | Ambien® | 5-12.5 mg for insomnia | Major effect is sedation Side effects include dizziness | Low birth weight; prematurity; growth restriction | 0.02-0.2% | • 2.5-5 hr | Possible sedation, respiratory depression | |



MEDICATION CHART (OPIOIDS, BENZODIAZEPINES, OTHER)

(This chart is intended for clinicians who provide primary care to pregnant and postpartum women)

Data current as of December 2016

Selected References

Ban, L., West, J., Gibson, J.E., Fiaschi, L., Sokal, R., Doyle, P., et al. (2014). First Trimester Exposure to Anxiolytic and Hypnotic Drugs and the Risks of Major Congenital Anomalies: A United Kingdom Population–Based Cohort Study. *PLoS One*, *9*(6).

Gilboa, S.M., Strickland, M.J., Olshan, A.F., Werler, M.M., & Correa, A. (2009). Use of Antihistamine Medications During Early Pregnancy and Isolated Major Malformations. *Birth Defects Research Part A: Clinical and Molecular Teratology,* 85(2), 137–50.

Hale, T.W. & Rowe, H.E. (2017). *Medications and Mothers' Milk*. Micromedex® Healthcare Series. 1974–2010. Greenwood Village, CO: Thomson Healthcare.

lqbal, M.M., Sobhan, T., & Ryals, T. (2002). Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatric Services*, *53*(1), 39–49.

Lexicomp online (accessed February 20, 2017) Copyright 1978–2017 Lexicomp, Inc.

Zedler, B.K., Mann, A.L., Kim, M.M., Amick, H.R., Joyce, A.R., Murrelle, E.L., et al. (2016). Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. *Addiction*, 111(12), 2115–2128.

Comments

The information should not be construed as dictating an exclusive course of treatment or procedure to be followed Variations in practice may be warranted.

- Medications vary in the amount and quality of data available about effects in human pregnancy. A better-studied medication may have more reported side effects than a less-studied medication because more is known about it, not necessarily because it is riskier.
- Data presented here are based on reports from and studies during human pregnancy.
- Risks of medications during pregnancy and lactation must be weighed against the risks of untreated symptoms.
 Treatment needs to be individualized

- If a patient is on other medications, consult with a pharmacist or other appropriate specialists for interaction information.
- As of June 30, 2015, the FDA required the removal of the pregnancy categories A, B, C, D, and X from all human
 prescription drug and biological product labeling. Required labeling includes relevant information about
 pregnancy testing, contraception, and infertility for health care providers.

Breastfeeding and Medications

- Reported side effects in breastfeeding infants are based on case reports and case series.
- The infant's age, size, and stability are important criteria to evaluate prior to prescribing a medication for maternal use.
- Premature infants and neonates, in general, are at greater risk for adverse effects than older/more mature infants.
- Medically unstable infants may be at higher risk for adverse effects of maternal medications.
- Medications with a Relative Infant Dose (RID) less than 10%, are considered relatively safe to use.
- Choose drugs with a short half-life, high protein binding, low oral bioavailability, or high molecular weight.
- Avoid random switching of medications based on data alone. Choose drugs for which published data is available, rather than those recently introduced.
- Medications used in the first 3-4 days postpartum generally produce sub-clinical levels in the infant due to the limited volume of milk.
- Avoid using medications when possible. Avoid using unnecessary herbal drugs, high dose vitamins, unusual supplements, etc.
- Pediatric-approved drugs are generally less hazardous if long-term history of safety is recognized.

Adapted from Hale, T.W. & Rowe, H.E. (2014). Medications and Mothers' Milk (16th ed.) New York, NY: Springer Publishing Company.

©2017 Wisconsin Association for Perinatal Care

Funded in part by the MCH Title V Services Block Grant through the MCHB/HRSA/U.S. DHHS.